Effects of Bubble-PEP After Open Heart Surgery on Blood Gases, Dyspnea, Secretion Status, and Pain (BUBBLE-PEP)

November 16, 2026 updated by: Hamide Erkan, Afyonkarahisar Health Sciences University

The Effect of Bubble-PEP Intervention After Open Heart Surgery on Arterial Blood Gas, Dyspnea, Secretion Status, and Pain: A Randomized Controlled Study

This randomized controlled study aims to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain in patients undergoing open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. A total of 92 adult patients undergoing coronary artery bypass grafting or heart valve surgery will be included. Participants will be randomly assigned to an intervention group (n=46) or a control group (n=46) using stratified block randomization based on surgical procedure.

Both groups will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry. In addition to standard care, the intervention group will receive Bubble-PEP therapy twice daily for three consecutive days following extubation. Each session will consist of three sets of 10 expirations.

Arterial blood gas parameters, dyspnea, respiratory secretion status, and pain will be assessed at baseline, during follow-up, and after completion of the intervention. Patient satisfaction will also be evaluated.

The study aims to determine whether adding Bubble-PEP therapy to standard postoperative care improves respiratory outcomes and contributes to evidence-based nursing care following open-heart surgery.

Study Overview

Detailed Description

Study Design and Setting This study is designed as a randomized controlled trial to investigate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on arterial blood gas parameters, dyspnea, respiratory secretion status, and pain following open-heart surgery.

The study will be conducted in the Cardiovascular Surgery Department and Intensive Care Unit of Afyonkarahisar Health Sciences University Health Research and Application Center, Türkiye. Ethical approval was obtained from the Non-Interventional Scientific Research Ethics Committee of Afyonkarahisar Health Sciences University on October 2, 2026 (Decision No. 740).

Participants and Sample Size The study will include 92 adult patients undergoing coronary artery bypass grafting (CABG) or heart valve surgery, with 46 patients assigned to each group.

The sample size was calculated using G*Power 3.1.9.7, based on an effect size of 0.659 for PaO2, a significance level of 0.05, and 80% statistical power. The initial sample size was 76 participants, which was increased to 92 to account for an anticipated 20% dropout rate.

Eligible participants will be aged 18 years or older, have undergone CABG or heart valve surgery, be extubated and hemodynamically stable, be able to communicate in Turkish, and provide informed consent.

Randomization and Blinding Participants will be allocated to intervention and control groups in a 1:1 ratio using stratified block randomization according to surgical type (CABG or heart valve surgery).

Computer-generated randomization lists will be prepared by an independent researcher who is not involved in intervention delivery or outcome assessment. Group allocation will be implemented using sequentially numbered, sealed envelopes.

Due to the nature of the intervention, participants and the researcher administering Bubble-PEP therapy cannot be blinded. However, outcome assessments will be conducted by an independent assessor blinded to group allocation. The statistician will also remain blinded to group identity until completion of the analysis.

Control Group Participants in the control group will receive standard postoperative care, including breathing exercises, chest percussion, and incentive spirometry.

Intervention Group Participants in the intervention group will receive Bubble-PEP therapy in addition to standard postoperative care.

The Bubble-PEP apparatus will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and a tube approximately 80 cm long with an internal diameter of 8 mm. A separate bottle and tube will be provided for each participant.

Bubble-PEP therapy will begin after extubation, once the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.

During the intervention, patients will be placed in an upright sitting position and instructed to inhale deeply through the nose and then exhale slowly, continuously, and in a controlled manner through the tube submerged in water.

The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

Outcome Measurements

The primary outcome measures will include:

Arterial blood gas parameters: PaO2, PaCO2, pH, HCO3-, base excess (BE), and oxygen saturation (SpO2).

Dyspnea severity assessed using the Modified Borg Dyspnea Scale. Respiratory secretion status and cough effectiveness assessed using a researcher-developed postoperative respiratory secretion and cough effectiveness assessment form.

Secondary outcome measures will include:

Pain intensity assessed using the Visual Analog Scale (VAS). Patient satisfaction assessed using a visual patient satisfaction scale.

Data Collection and Assessment Schedule Preoperative demographic and clinical data will be collected after obtaining written informed consent. Preoperative dyspnea and pain assessments will also be performed.

The first calendar day following extubation will be designated as Day 1 (G1). Baseline postoperative assessments will be performed on Day 1, before the first Bubble-PEP session, preferably between 09:00 and 10:00, provided that at least six hours have elapsed since extubation and the patient is hemodynamically stable.

Follow-up assessments will be performed on Days 2 and 3 (G2 and G3), between 09:00 and 10:00, before the daily intervention.

The final assessment will be performed on Day 4 (G4), between 09:00 and 10:00, following completion of the three-day intervention period. Patient satisfaction will also be evaluated during the final assessment.

Arterial blood gas results obtained as part of routine clinical care will be recorded from patient records.

Statistical Analysis Data will be analyzed using SPSS software. Descriptive statistics will include frequencies, percentages, means, and standard deviations.

Depending on the distribution of the data, independent-samples t-tests or Mann-Whitney U tests will be used for between-group comparisons. Paired t-tests or Wilcoxon signed-rank tests will be used for within-group comparisons.

Repeated-measures analysis of variance or Friedman tests will be used to evaluate changes over time, as appropriate. Exploratory subgroup analyses based on surgical type may be performed if the sample size is sufficient.

Statistical significance will be set at p < 0.05.

Study Type

Interventional

Enrollment (Estimated)

92

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Centre
      • Afyonkarahisar, Centre, Turkey (Türkiye), 03100
        • Afyonkarahisar University of Health Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Having undergone Coronary Artery Bypass Graft (CABG) or heart valve surgery,
  • Being 18 years of age or older,
  • Not having undergone postoperative revision surgery,
  • Having no neurological or severe cognitive impairment, and no postoperative delirium,
  • Being extubated and hemodynamically stable,
  • Being able to communicate in Turkish,
  • Being willing to participate in the research.

Exclusion Criteria:

  • Having undergone a surgical procedure other than CABG or heart valve surgery,
  • Patients who require revision surgery during the postoperative period,
  • Patients with neurological or severe cognitive impairment,
  • Patients experiencing postoperative delirium,
  • Individuals aged 18 years or younger,
  • Patients who have not been extubated,
  • Patients who are hemodynamically unstable,
  • Individuals with whom it is not possible to communicate in Turkish, or those who are unwilling to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bubble-PEP Intervention Group

Patients in the intervention group will receive Bubble Positive Expiratory Pressure (Bubble-PEP) therapy in addition to routine postoperative care following open-heart surgery. I will evaluate the intervention's effects on arterial blood gas parameters, dyspnea, secretion status, and pain.

A researcher-prepared Bubble Positive Expiratory Pressure (Bubble-PEP) device will be used in addition to standard postoperative care.

The device will consist of a 1.5-liter plastic bottle filled with water to a depth of 10 cm and an approximately 80-cm-long tube with an internal diameter of 8 mm. Each patient will be provided with an individual bottle and tube.

Bubble-PEP therapy will be initiated after extubation when the patient is conscious, hemodynamically stable, and considered clinically suitable by the treating physician.

During the intervention, the patient will be placed in an upright sitting position and instructed to inhale deeply through the nose, followed by slow, controlled, and continuous exhalation through the tube submerged in water.

The intervention will be administered twice daily, in the morning and afternoon, on the first, second, and third days after extubation. Each session will consist of three sets of 10 expirations, totaling 30 expirations per session.

Other Names:
  • Bottle Positive Expiratory Pressure (Bottle-PEP)
No Intervention: Control Group

Patients in the control group will receive routine postoperative care following open-heart surgery, with no additional interventions applied. I will assess arterial blood gas parameters, dyspnea, secretion status, and pain.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Arterial Oxygen Partial Pressure(PaO₂)
Time Frame: Days 1, 2, and 3 post-extubation

Arterial oxygen partial pressure(PaO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Carbon Dioxide Partial Pressure(PaCO₂)
Time Frame: Days 1, 2, and 3 post-extubation

Arterial carbon dioxide partial pressure (PaCO₂) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in PaCO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Blood pH
Time Frame: Days 1, 2, and 3 post-extubation

Arterial blood pH will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in arterial blood pH will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Oxygen Saturation (SaO₂)
Time Frame: Days 1, 2, and 3 post-extubation

Arterial oxygen saturation (SaO₂, %) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in SaO₂ levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Bicarbonate Level (HCO₃-)
Time Frame: Days 1, 2, and 3 post-extubation

Arterial bicarbonate levels (HCO₃-, mmol/L) will be measured using arterial blood samples obtained from patients following open-heart surgery. Changes in HCO₃- levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Arterial Blood Base Excess (BE)
Time Frame: Days 1, 2, and 3 post-extubation

Arterial blood base excess (BE, mmol/L) will be assessed using arterial blood samples obtained from patients following open-heart surgery. Changes in BE levels will be evaluated and compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation
Change in Dyspnea Severity
Time Frame: Days 1, 2, and 3 post-extubation

Dyspnea severity will be assessed in patients following open heart surgery using a standardized dyspnea assessment scale. Changes in dyspnea scores will be evaluated and compared between the Bubble-PEP intervention group and the control group. Higher scores will indicate greater dyspnea severity.

Days 1, 2, and 3 post-extubation
Change in Respiratory Secretion Status
Time Frame: Days 1, 2, and 3 post-extubation

Respiratory secretion status will be assessed in patients following open heart surgery to evaluate the effects of Bubble Positive Expiratory Pressure (Bubble-PEP) therapy on airway secretion clearance. Changes in secretion status will be evaluated and compared between the intervention and control groups.

Days 1, 2, and 3 post-extubation

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Postoperative Pain Intensity
Time Frame: Days 1, 2, and 3 post-extubation

Postoperative pain intensity will be assessed using the Numeric Rating Scale (NRS), ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in pain scores will be compared between the Bubble-PEP intervention group and the control group.

Days 1, 2, and 3 post-extubation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

November 16, 2026

Primary Completion (Estimated)

April 1, 2027

Study Completion (Estimated)

August 30, 2027

Study Registration Dates

First Submitted

November 10, 2026

First Submitted That Met QC Criteria

November 16, 2026

First Posted (Actual)

November 18, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 16, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be made publicly available or shared with other researchers. The study involves patients undergoing open-heart surgery, and participant confidentiality and data privacy will be maintained in accordance with the approved research protocol and applicable ethical and data protection requirements.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe